Rhythm Pharma's Imcivree Wins UK Approval For Obesity, Hunger Control

Comments
Loading...
  • Britain's Medicines & Healthcare Products Regulatory Agency (MHRA) has approved Rhythm Pharmaceuticals Inc RYTM Imcivree (setmelanotide) for obesity and the control of hunger.
  • Related: Rhythm Pharma's Imcivree Gets European Approval For Obesity, Control of Hunger Associated With Genetic Mutations.
  • The approval covers adults and children six years of age & above, with genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency, or biallelic leptin receptor (LEPR) deficiency.
  • Imcivree was selected for evaluation as a "Highly Specialized Technology" by the National Institute for Health and Care Excellence (NICE). 
  • NICE is scheduled to review the dossier for Imcivree in December 2021. 
  • Guidance for coverage of Imcivree under the U.K.'s National Health Service (NHS) is anticipated in Q2 of 2022.
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: RYTM stock is down 1.19% at $12.42 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!